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ABSTRACT 
 
Michael G. Harley: Influence of Metformin on T-Cell mRNA Expression 
(Under the direction of Melinda Beck) 
 
 
Obesity has become a serious public health concern worldwide, being the fifth leading risk for 
global deaths. It has been associated with multiple health conditions, such as cardiovascular disease, 
cancer, and diabetes. In 2009, it was identified as an independent risk factor for influenza morbidity and 
mortality. Studies have demonstrated that obese individuals have an impaired T-cell response, resulting 
in twice the risk of influenza infection despite vaccination. With vaccination being the best method of 
protection, it is paramount to understand why T-cell impairment is present. The link between T-cell 
function and metabolism has led to research that indicates that T-cells of obese individuals are in an 
activated metabolic state without being stimulated. It has been suggested that chronic exposure to this 
activated state may be impairing the immune response. The metabolic drug Metformin may have the 
potential to shift T-cells back to a resting metabolic state because of its influence on T-cell metabolism 
and function. This study was designed to assess the influence of Metformin on the mRNA expression of 
key metabolic indicators by T-cells. We show that Metformin influences mRNA expression and that it 
maintains expression levels of key indicators after influenza exposure. This study elaborates on the 
potential for Metformin to serve as an immunoenhancing agent in order to reduce the risk of influenza 
infection in obese individuals.    
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Chapter 1: Introduction 
Despite recently surging as a main topic in public health discourse, obesity is not new to the 
health history of humans. What does seem to be new, however, is the negative implications of obesity. 
When considering the historical context of obesity, body fat seems to have been an advantage during 
times of pestilence and famine. The ability to store excess energy in the form of fat and then be able to 
use that energy over a long period of time, appears to have determined whether early humans lived or 
died.2 Towards the end of the 19th century, excess fat was no longer culturally considered desirable.  Not 
until the 20th century did public health officials begin to understand the association between morbidity 
and obesity. Therefore, describing obesity as a disease, with a specific pathology, is only about 100 years 
old.2 The exponential increase in obese individuals over the past 60 years and the increase in morbidity 
due to obesity, eventually led the World Health Organization to declare it a global epidemic and 
worldwide public health crisis.2  
Defined by a BMI of ≥ 30 (weight in kg/height in m2), obesity has increasingly become a 
detriment to human health. In 2016 alone, 650 million adults worldwide were obese, representing 13% 
of the world’s adult population.3 Obesity has become such an epidemic, that it now kills more people 
than does being underweight. The burden of obesity extends beyond individual health. Obesity results in 
both an individual and national economic burden. In 2014, the global economic impact of obesity was 
estimated to be $2.0 trillion.4 A large proportion of this expenditure is health care, but obesity also 
produces economic burden in the form of lost human capital.4 When considering health implications, 
obesity has been associated with multiple noncommunicable diseases such as: cardiovascular disease, 
diabetes, and some cancers.3 Additionally, obesity has been associated with an increased risk of 
respiratory infection, in particular, influenza infection.5,6 The link between obesity and influenza 
infection is so profound, that in 2009, the CDC identified obesity as an independent risk factor for 
increased morbidity and mortality due to influenza infection.1  
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Infecting 5-10% of adults yearly, the influenza virus is one of the most lethal infectious viruses. 
Since 2010, it is estimated that influenza infection has resulted in 12,000-56,000 deaths and 9 million-35 
million cases of severe illness.7 The most recent 2009 influenza pandemic claimed the lives of hundreds 
of thousands of people. The CDC estimates that between 150,000 and 575,000 people died during the 
2009 pandemic.8 With viral strains changing every year, the risk of an outbreak threatens the public’s 
health. Although complete protection from infection is not currently possible, vaccination provides and 
remains the best method of reducing risk of infection. The influenza vaccine functions by exposing the 
immune system to a small amount of inactivated influenza virus and facilitating the development of 
immunological memory. In the case of future exposure to influenza, the immune system should be able 
to recognize the virus and elicit a specific response to prevent virus replication and severe illness.  
Because obese individuals have an increased risk of influenza infection, vaccination should be 
administered in order to provide the best form of protection. However, it has been reported that 12 
months post-vaccination, obese individuals have significantly lower levels of antibodies when compared 
to healthy weight individuals.9 Additionally, the T cells of obese individuals demonstrate significantly 
decreased activation and expression of functional proteins.9 In 2017, it was found that despite being 
vaccinated against influenza, obese individuals have twice the risk of developing influenza or influenza-
like illness.10 These findings are daunting due to the fact that the best method of protection, vaccination, 
is unable to protect a large part of the population from potentially deadly infection.  
Due to the role of T-cells in immune function and response to influenza infection, it is important 
to understand the reason behind their impairment in obese individuals. Numerous studies have 
demonstrated the link between T-cell function and the internal metabolic profile of the cell.11-13 T-cells 
can exist in two unique metabolic profiles that drive their function. An adequate immune response is 
energetically expensive and, therefore, is regulated via metabolic pathways. After synthesis in the 
thymus, mature resting T cells exist in a metabolic state that favors energy production since the 
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demands on resting T cells are moderately low.12 Relying predominantly on breakdown of fatty acids and 
pyruvate oxidation in the TCA cycle, resting T cells increase energy stores in preparation of future 
immune responses.12 Conversely, T cells responding to an antigen require a different metabolic profile 
that matches their function. During an immune response to influenza infection, T cells proliferate in 
order to successfully combat the activities of influenza virus. Increased growth and replication requires 
biosynthesis of lipids, nucleic acids, and proteins.12 This demand for biosynthesis is met by a change in 
metabolism that is characterized by increased aerobic glycolysis and decreased breakdown of fatty 
acids.12 This metabolic profile in which glucose metabolism is increased, matches the high energy needs 
of an activated T-cell, allowing it to function properly as it counteracts the effects of influenza infection.  
Regulating the two metabolic states of T cells are mammalian target of rapamycin (mTOR) and 
AMP-activated protein kinase (AMPK). Upon activation of T-cells, mTOR is activated and promotes 
glucose metabolism via posttranslational effects, thus inducing the metabolic state in which aerobic 
glycolysis predominates.12 To facilitate glucose metabolism, GLUT-1 is upregulated to the cell surface, 
allowing for cell growth and proliferation. In order to complete the shift to aerobic glycolysis, mTOR 
indirectly downregulates CPT-1, an enzyme involved in fatty acid breakdown, by promoting fatty acid 
synthesis.12 The increase in lipid synthesis inhibits CPT-1 activity. Finally, the shift to aerobic glycolysis 
also results in upregulation of lactate dehydrogenase, an enzyme that converts glycolysis products to 
lactate. Opposing mTOR and promoting a resting metabolic state, AMPK focuses on increasing energy 
stores in the cell. Activated by an increased ratio of AMP to ATP, AMPK inhibits mTOR and upregulates 
CPT-1 activity. AMPK is the key regulator in the metabolic state in which energy is primarily produced via 
oxidative phosphorylation, thus increasing energy stores and preparing T-cells for rapid cell growth 
required during an immune response.12   
Our lab has preliminary evidence indicating that the T-cells of obese individuals are in an 
excessive glycolytic state, characteristic of activated T-cells, without being activated. Shifting to an 
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activated metabolic state without stimulation may account for the impairment observed once T-cells of 
obese individuals are exposed to influenza.  The pathway upregulating mTOR is also known to be 
stimulated by growth factors, such as those circulating in high amounts in obese individuals. Due to the 
fact that chronic stimulation of T-cells results in reduced T-cell proliferation and effector function12, it is 
possible that chronic stimulation of T-cells of obese individuals by excess nutrients is resulting in cellular 
dysfunction thus preventing adequate response to influenza infiltration.  
Clearly, activities of mTOR are dominant in T-cells of obese individuals. Although an inhibitor of 
mTOR, AMPK seems unable to shift cells to metabolism that characterizes resting T cells. Metformin, the 
best treatment for obese Type-2 diabetes, reduces blood sugar levels by activating AMPK and has been 
implicated as influencing immune cells. B-cells have been found to express higher levels of antibodies 
when exposed to metformin.14 Additionally, metformin has been found to activate AMPK in T cells, as 
well as increase memory T cell formation.15 Metformin’s ability to inhibit mTOR, via AMPK, may provide 
a way to shift activated T-cells of obese individuals back to a resting metabolic state in order to restore 
cellular function and improve immune response. To assess metformin influence on the metabolism of T-
cells of obese individuals, this study examined mRNA expression of GLUT-1, CPT-1, and LDH in T-cells 
unstimulated compared to T-cells stimulated with influenza virus. We hypothesized that the T-cells 
exposed to Metformin will express higher mRNA levels of CPT-1 and lower mRNA levels of GLUT-1 and 
LDH.  
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Chapter 2: Methods and Materials 
 Study Design 
The Beck lab has been conducting a large prospective observational study since 2009. 
Participants of the study were recruited from the University of North Carolina at Chapel Hill Family 
Medicine Center, an academic outpatient primary care facility. All participants of this study were adults 
who received their annual trivalent inactivated influenza vaccine for the respective year of the study. 
During this study, blood was drawn before vaccination and 30 days post-vaccination. Exclusion criteria 
were immunosuppression, self-reported use of immunomodulator or immunosuppressive drugs, acute 
febrile illness, history of hypersensitivity to any influenza vaccine components, history of Guillian-Barre 
syndrome, or use of theophylline preparations or warfarin.5 All procedures were approved by the 
Biomedical Institutional Review Board at the University of North Carolina at Chapel Hill.1 
At enrollment, informed written consent, demographic characteristics, height, weight, and a 
blood sample were obtained. Next, a single dose of the trivalent inactivated influenza vaccine was 
administered in the deltoid muscle. Body mass index (BMI) for each participant was calculated and 
defined as healthy weight (BMI of 18.5-24.9), overweight (BMI of 25-29.9), or obese (BMI of ≥ 30). 
Participants then returned 30 days later for a post vaccination blood draw. Blood samples were 
processed into serum and peripheral blood mononuclear cells (PBMCs).  
A total of 1803 subjects were enrolled between 2014 and 2017. A sample group of 46 
participants, comprised of 27 obese Type-2 diabetics individuals taking Metformin and 19 obese non-
diabetic individuals not taking Metformin, were selected for this study. Race was dichotomized into 
African-American and Caucasian. Demographics of each study group are presented in Table 1 and Table 
2. Peripheral blood mononuclear cells (PBMCs) obtained 30 days post-vaccination were used for the 
experiments presented in this manuscript.    
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 PBMC Isolation and Stimulation 
Frozen PBMC samples were retrieved from -195°C liquid nitrogen tanks and thawed in a 37°C 
water bath. One mL of RPMI-1640 cell culture media was added to thawed PBMCs, mixed by pipet, and 
transferred to a 15 mL conical tube. Tubes were centrifuged and PBMCs pellets were resuspended in 1 
mL of cell media. Cells were allowed to rest for 3 hours at 37°C and 5% CO2. Cells were then divided into 
three conditions: unstimulated, influenza stimulated, and ConA (positive control) stimulated. Twenty μL 
of H1N1 virus were added to PBMCs of influenza stimulated condition and allowed to rest for 66 hours. 
Two μL of ConA (1μg/μL) were added to PBMCs of positive control condition and allowed to rest for 48 
hours. PBMCs rested at 37°C and 5% CO2. After resting period, PBMCs were centrifuged and stored, 
without media, in -80°C until needed for RNA extraction.  
 Total RNA Purification and RT-qPCR 
Cell pellets were resuspended in TRIzol to lyse cells and release cell components, including RNA. 
Total RNA was separated, isolated, purified, and quantitated. Total RNA was diluted into 10 μL RNAase-
free water and stored at -80 °C until use. Using RT-qPCR, mRNA expression of CPT-1, GLUT-1, and LDH 
was measured. β-Actin was used as control. Reactions were conducted in PCR 96-well plates and run in 
BIO-RAD thermocycler. The iScript™ RT Supermix was added to total RNA samples to synthesize cDNA. 
Samples were then diluted and gene-specific primers and iTaq™ Universal SYBR® Green Supermix added. 
Samples were then loaded into rt-PCR instrument and amplification occurred. Reagents and primers 
were from BIO-RAD.   
Statistical Analysis 
Mean comparisons in Figure 1 were performed by multiple t-tests. Mean comparison in Figure 2 
and Figure 3 were performed by Welch’s t test (unpaired). GraphPad Prism version 7 software was used 
to perform the analyses and construct graphs.  
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Chapter 3: Results 
In this study, we measured mRNA expression for specific metabolic genes using Ct values 
produced during RT-qPCR. The Ct value corresponds to the number of cycles required for mRNA levels to 
be detected and thus exceed a background level. Ct levels are significant because they are inversely 
proportional to the amount of target nucleic acid in the sample. Therefore, lower Ct values correspond 
to higher mRNA levels of the target gene.  
3.1 No significant difference in mRNA expression of GLUT-1, CPT-1, and LDH observed between 
OB+MET and OB groups 
When comparing obese subjects taking Metformin to those not taking Metformin within each 
PBMC condition, there were no significant differences in the mRNA expression of each key protein 
(GLUT-1, CPT-1, and LDH). Still, the OB+MET group demonstrated higher levels GLUT-1, CPT-1, and LDH 
mRNA in unstimulated and flu stimulated PBMCs. This trend remained true except in the mRNA 
expression of GLUT-1 by influenza stimulated PBMCs of the OB group. Once stimulated, PBMCs of the 
OB group began to express more GLUT-1 mRNA compared to the OB+MET group, but mRNA levels of 
CPT-1 and LDH remained lower compared to the OB+MET group (Figure 1).   
3.2 OB+MET group showed higher overall mRNA expression compared to OB group in unstimulated 
PBMCs 
When considering the condition in which PBMCs were left unstimulated, we observed that 
obese individuals taking Metformin expressed a higher amount of total mRNA (Figure 3). Total mRNA 
means that we considered the average Ct value for each mRNA and averaged those values to depict an 
overall level of mRNA expression for each group.  
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3.3 OB and OB+MET showed same overall mRNA expression in influenza stimulated PBMCs 
Influenza stimulated PBMCs of both obese individuals taking Metformin and obese individuals 
not taking Metformin expressed equal amounts of total mRNA (Figure 2).  
3.4 CPT-1 mRNA expression was higher in the OB+MET group in both unstimulated and influenza 
stimulated PBMCs 
In both the unstimulated and influenza stimulated conditions, PBMCs of the OB+MET group 
expressed higher levels of CPT-1 mRNA compared to PBMCs of the OB group (Figure 1). For 
unstimulated cells, OB+MET group (Ct=26.87) compared to OB group (Ct=28.25). For influenza 
stimulated cells, OB+MET group (Ct=27.17) compared to OB group (Ct=28.34).   
3.5 GLUT-1 and LDH mRNA expression changes in unstimulated PBMCs of the OB group when 
stimulated with influenza 
Stimulation with influenza resulted in an increase in mRNA expression of both GLUT-1 and LDH 
in PBMCs of obese individuals not taking Metformin (Figure 1). Expression of CPT-1 mRNA remained the 
same after influenza stimulation.  
3.6 mRNA expression of GLUT-1, CPT-1, and LDH in unstimulated PBMCs of OB+MET group was 
unchanged with influenza stimulation  
Despite exposure to influenza, PBMCs of obese individuals taking Metformin expressed equal 
amounts of GLUT-1, CPT-1, and LDH mRNA as when unstimulated (Figure 1). This was not observed for 
PBMCs of obese individuals not taking Metformin.  
 
 
9 
 
Chapter 4: Discussion 
The threat that influenza infection imposes on the health of obese individuals is of serious 
concern. Currently, vaccination provides the best form of protection, but is less effective in obese 
individuals. With a significant amount of the world’s population being obese, public health leaders must 
develop a way of reducing the risk of infection in the obese population. Studies have demonstrated that 
the immune cells involved in fighting off influenza are impaired in obese individuals. T-cells responsible 
for targeting and ridding the body of infected cells have been found to be less active and dysfunctional 
in obese individuals, which may account for the fact that obese individuals are twice as likely to be 
infected with influenza despite vaccination.  
The relationship between T-cell function and metabolism has been well documented and 
indicates that regulation of cell metabolism is influenced by whether T-cells are resting or activated. In 
the activated state, T-cell metabolism is characterized by aerobic glycolysis and an increase in 
biosynthesis. In contrast, resting T-cells exhibit a metabolic profile where oxidative phosphorylation via 
the TCA cycle and electron transport chain predominate. Although beneficial when T-cells need to elicit 
an immune response, chronically being in the activated metabolic state can be detrimental to cell 
viability and function. Data in our lab indicates that T-cells of obese individuals are chronically in an 
activated state due to the fact that an excessive glycolytic metabolic profile is observed without 
stimulus. This may explain the dysfunction in T-cells of obese individuals. The use of Metformin to 
restore T-cell function has been implicated based on research surrounding the effects of Metformin on 
B-cell function and T-cell metabolism. Two key regulators of T-cell metabolism, mTOR and AMPK, have 
been found to be affected by Metformin. GLUT-1, CPT-1, and LDH are known targets of mTOR and AMPK 
that influence the metabolic state of the cell and therefore its function.  
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When we considered mRNA expression of GLUt-1, CPT-1, and LDH individually, we found that 
were no significant differences in expression between obese individual taking Metformin and those not 
taking Metformin, regardless of whether PBMCs were unstimulated or influenza stimulated.  Still, other 
trends were observed that indicate Metformin influences T-cell metabolism. In unstimulated PBMCs, the 
group taking Metformin expressed higher mRNA levels of GLUT-1, CPT-1, and LDH. Knowing that fatty 
acid oxidation is predominant during the resting state, we expected CPT-1 mRNA levels to be higher in 
the OB+MET group assuming that Metformin would be able to return T-cells in an excessive glycolytic 
state to a resting metabolic state. Although mRNA levels of GLUT-1 and LDH were higher in Metformin-
exposed unstimulated T-cells, which was not expected, the fact that the OB+MET group demonstrated 
higher mRNA levels indicates that Metformin is influencing in a way that merits further investigation.  
Interestingly, we found a deviation from the general trend. PBMCs of obese individuals not 
taking Metformin expressed higher mRNA levels of GLUT-1 once stimulated with influenza. This was not 
observed for the other two mRNAs. The importance of GLUT-1 in T-cell activation and function has been 
well described16, therefore, it is possible that this deviation is explained by the importance of GLUT-1 in 
ensuring that T-cells can function once activated by influenza. We also observed that unstimulated 
PBMCs exposed to Metformin, expressed higher overall mRNA levels compared to unstimulated PBMCs 
not exposed to Metformin. Now, once influenza stimulated, overall mRNA levels were equal for both 
OB+MET and OB groups. The levels of mRNA expression for the OB+MET group remained the same once 
PBMCs were stimulated, whereas, the OB group demonstrated an increase in overall mRNA expression 
once cells were exposed to influenza. This suggests that T-cells not exposed to Metformin enhance the 
metabolism of the activated state. This is intriguing since we know that the T-cells of obese individuals 
are already activated. Therefore, it seems that once exposed to influenza, these cells are activated even 
more, potentially leading to further dysfunction. On the other hand, Metformin seems to prevent this 
11 
 
further increase in expression of glycolytic proteins and may potentially be shielding T-cells from further 
damage and dysfunction. 
As previously mentioned, GLUT-1 mRNA expression increased in the OB group once PBMCs were 
stimulated with influenza. Similarly, mRNA expression of LDH also increased under the same conditions. 
This was not observed for CPT-1. We understand both GLUT-1 and LDH to be involved in upregulated 
metabolism of glucose in the activated metabolic state of a T-cell. Again, it is apparent that further 
activation, via influenza stimulation, of already activated T-cells is occurring. It is resulting in an increase 
in mRNA expression of proteins involved in maintaining the glycolytic metabolic state. Not only is there 
an increase in mRNA of glucose transporters, but cells are also increasing mRNA levels of the enzyme 
that will help metabolize the glucose. These results suggest that there is no impairment in the regulation 
of mTOR in the absence of Metformin. This is important because of other observations that were made. 
We found that influenza stimulation did not influence mRNA expression of GLUT-1, CPT-1, and LDH in 
the OB+MET group. Unlike in the OB group, Metformin exposure seemed to maintain mRNA expression 
of key proteins at the same levels they were at before further activation.  
These findings have considerable implications regarding the role of Metformin. It has been 
suggested that Metformin may serve a therapeutic role by returning activated T-cells to a resting 
metabolic state. Our findings depict that Metformin may actually prevent already activated T-cells from 
becoming even more activated and therefore increasing aerobic glycolysis. Considering the effects that 
further activation may have on T-cells, such as cell exhaustion, which may lead to additional impairment, 
these apparent effects of Metformin may be promising. We know that obese individuals have a 
dysfunctional immune response when exposed to influenza. It is possible that this is due to the 
additional activation that occurs when cells encounter influenza. There may be a threshold of activation 
that is surpassed with influenza stimulation leading to an inability of the cell to function. As a result, T-
cells are unable to respond. This may account for the increased risk of influenza infection observed in 
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obese individuals. Exposure to Metformin may prevent this threshold from being passed and allow T-
cells to respond to infection.   
Our study had several limitations. Importantly, we were unable to confirm whether subjects 
were actually taking Metformin at the time of blood draw. Despite having access to medical records, 
which stated if subjects were prescribed Metformin, we did not have any information on compliance. 
This is important since we are assuming that subjects were taking Metformin. Secondly, there may be 
genetic variability in how Metformin is metabolize by PBMCs. If different people metabolize Metformin 
differently, this will influence the role it plays within cells. Metformin may also be metabolized 
differently by different types of immune cells. This raises another important limitation. In our study, we 
isolated a collection of immune cells. We evaluated both B-cells and T-cells. Therefore, we did not 
isolate specific types of T-cells and investigate the effects of Metformin. Metformin may have different 
effects on the metabolism of different types of T-cells, such as CD4 and CD8 T-cells. Finally, we also had 
a small sample size, which limited the power of our study.  
Influenza infection is a serious threat to public health. In particular, obese individuals are at 
greater risk of infection because of impaired T-cells. Activation of T-cells, without influenza stimulation, 
may be causing this observed impairment. The results of this study indicate that Metformin does 
influence the metabolic state of T-cells, but the details of this influence are unclear. It appears that 
Metformin is able to maintain the metabolic state of T-cells even after they are stimulated to increase 
glucose metabolism through aerobic glycolysis. This may prove to be beneficial towards how T-cells 
respond to influenza. The role of Metformin in influencing T-cell response is promising. Hopefully, it is 
able to serve as an immunoenhancer, providing protection to a significant percentage of our population 
and reducing the risk of influenza infection and associated health complications.     
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Table 1. OB+MET group demographics 
Subject 
No. 
Sex Age Race BMI BMI 
Category 
Metformin 
1 Female 31.6 African 
American 
33.1 4 Yes 
2 Female 31.9 African 
American 
34.1 4 Yes 
3 Female 42.0 African 
American 
42.9 5 Yes 
4 Female 43.7 African 
American 
37.2 4 Yes 
5 Female 44.7 African 
American 
39.6 4 Yes 
6 Female 46.4 African 
American 
59.5 5 Yes 
7 Female 50.8 African 
American 
41.4 5 Yes 
8 Female 51.1 African 
American 
34.6 4 Yes 
9 Female 51.9 African 
American 
40.4 5 Yes 
10 Female 52.8 African 
American 
40.2 5 Yes 
11 Female 53.0 African 
American 
37.2 4 Yes 
12 Female 54.0 African 
American 
36.8 4 Yes 
13 Female 55.0 African 
American 
37.0 4 Yes 
14 Female 55.6 African 
American 
34.6 4 Yes 
15 Female 56.1 African 
American 
36.8 4 Yes 
16 Female 61.7 African 
American 
34.3 4 Yes 
17 Female 51.3 Caucasion 43.8 5 Yes 
18 Female 52.0 Caucasion 37.1 4 Yes 
19 Female 52.6 Caucasion 32.4 4 Yes 
20 Female 64.0 Caucasion 50.8 5 Yes 
21 Male 45.3 African 
American 
42.2 5 Yes 
22 Male 46.2 African 
American 
41.0 5 Yes 
23 Male 60.0 African 
American 
31.3 4 Yes 
24 Male 43.8 Caucasion 41.0 5 Yes 
25 Male 44.8 Caucasion 41.0 5 Yes 
26 Male 48.2 Caucasion 30.5 4 Yes 
27 Male 60.6 Caucasion 36.4 4 Yes 
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Table 2. OB group demographics 
Subject No. Sex Age Race BMI BMI Category 
1 Female 41.8 African 
American 
43.4 5 
2 Female 43 African 
American 
37.7 4 
3 Female 45.9 African 
American 
37 4 
4 Female 47.4 African 
American 
61.1 5 
5 Female 53 African 
American 
34.7 4 
6 Female 52 African 
American 
35.1 4 
7 Female 57 African 
American 
36.6 4 
8 Female 56.6 African 
American 
36 4 
9 Female 61.8 African 
American 
32.9 4 
10 Female 53 Caucasion 32.3 4 
11 Male 49.8 Caucasion 30.8 4 
12 Male 59.6 Caucasion 33.9 4 
13 Female 29.4 African 
American 
30.4 4 
14 Female 60.7 African 
American 
32.9 4 
15 Female 63.2 African 
American 
41.7 5 
16 Female 51.6 Caucasion 34.6 4 
17 Female 59.4 Caucasion 33.8 4 
18 Male 55.1 Caucasion 32.1 4 
19 Male 64.7 Caucasion 39.3 4 
 
 
Table 3. Total Sample Subject Demographics 
 
Obese Metformin-treated Diabetic Obese Non-Diabetic 
Participants (n) 27 19 
BMI (mean ± 
SE) 
38.8 ± 1.2 36.6 ± 1.6 
Age (mean ± 
SE) 
50 ± 1.5 53 ± 2 
Sex (M/F) 7/20 4/15 
Race (B/W) 19/8 12/7 
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Figure 1. mRNA expression of GLUT-1, LDH, and CPT-1 comparing OB+MET and OB groups under 
unstimulated, influenza stimulated, and positive control conditions.  
No significant differences observed. Ct values correspond to the inverse of mRNA levels. Therefore, 
smaller Ct values mean higher mRNA levels. In unstimulated PBMCs, the OB+MET group expressed 
higher mRNA levels of GLUT-1, CPT-1, and LDH compared to the OB group. Once stimulated with 
influenza, PBMCs of the OB+MET group expressed the similar mRNA levels of GLUT-1, CPT-1, and LDH. 
After influenza stimulation, PBMCs of OB group expressed higher mRNA levels of GLUT-1 and LDH. 
Multiple comparisons t-test was conducted for analyses.   
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Figure 2. Comparing overall mRNA expression of influenza stimulated PBMCs 
When considering influenza stimulated PBMCs, overall mRNA expression was similar for both the 
OB+MET (Ct=27.7) and OB (Ct=27.75) groups. Overall mRNA expression, represented by Ct value, was 
calculated by averaging the Ct means for GLUT-1, CPT-1, and LDH mRNA expression.  
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Figure 3. Comparing overall mRNA expression of unstimulated PBMCs 
When considering unstimulated PBMCs, the OB+MET (Ct=27.57) group expressed higher levels of overall 
mRNA expression compared to the OB (Ct=29.15) group. Overall mRNA expression represents a 
combination of total mRNA between GLUT-1, CPT-1, and LDH. Overall mRNA Ct value (mRNA expression) 
was calculated by averaging the Ct means for GLUT-1, CPT-1, and LDH.  
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